The EHA Research Roadmap: Malignant Lymphoid Diseases

Normal Hematopoiesis;

• Publication year

  2022

• Venue

  HemaSphere

• Publication date

  2022-05-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/HS9.0000000000000726PMID 35620592PMCID 9126526
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

  2022cited by this paper
• Molecular map of chronic lymphocytic leukemia and its impact on outcome

  2022cited by this paper
• Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

  2021cited by this paper
• Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.

  2021cited by this paper
• Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant

  2021cited by this paper
• Thyroid MALT lymphoma: self-harm to gain potential T-cell help

  2021cited by this paper
• Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.

  2021cited by this paper
• Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup

  2021cited by this paper
• MRD Assessment in Multiple Myeloma: Progress and Challenges

  2021cited by this paper
• Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study

  2021cited by this paper
• Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia

  2021cited by this paper
• Front‐line management of post‐transplantation lymphoproliferative disorder in adult solid organ recipient patients — A British Society for Haematology Guideline

  2021cited by this paper
• Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT

  2021cited by this paper
• Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score

  2021cited by this paper
• Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells

  2021cited by this paper
• Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma

  2021cited by this paper
• MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

  2021cited by this paper
• Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients.

  2021cited by this paper
• Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

  2021cited by this paper
• Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised contro

  2021cited by this paper
• Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial

  2021cited by this paper
• Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

  2021cited by this paper
• Hematological cancers in individuals infected by HIV.

  2021cited by this paper
• Osteonecrosis in Adults With Acute Lymphoblastic Leukemia: An Unmet Clinical Need

  2021cited by this paper
• Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy

  2021cited by this paper
• Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape.

  2021cited by this paper
• HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.

  2021cited by this paper
• Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

  2021cited by this paper
• Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US

  2021cited by this paper
• Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium.

  2021cited by this paper
• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

  2021cited by this paper
• Improving the identification of frail elderly newly diagnosed multiple myeloma patients

  2021cited by this paper
• Past, present and future of prognostic scores in follicular lymphoma.

  2021cited by this paper
• Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

  2021cited by this paper
• Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

  2021cited by this paper
• Detection of gene fusion transcripts in Peripheral T-cell Lymphoma using a multiplexed targeted sequencing assay.

  2021cited by this paper
• Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified

  2021cited by this paper
• Immunodeficiency-associated Hodgkin lymphoma

  2021cited by this paper
• Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders.

  2021cited by this paper
• Richter Syndrome

  2021cited by this paper
• Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.

  2021cited by this paper
• PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.

  2021influential reference
• Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

  2021cited by this paper
• No survival improvement in patients with high‐risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades

  2021cited by this paper
• Multiple myeloma

  2021cited by this paper
• Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma

  2020cited by this paper
• Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2020cited by this paper
• Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes.

  2020cited by this paper
• Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.

  2020cited by this paper
• Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.

  2020cited by this paper
• Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 stud

  2020cited by this paper
• Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.

  2020cited by this paper
• Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma.

  2020cited by this paper
• A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.

  2020cited by this paper
• Experience with provisional WHO‐entities large B‐cell lymphoma with IRF4‐rearrangement and Burkitt‐like lymphoma with 11q aberration in paediatric patients of the NHL‐BFM group

  2020cited by this paper
• Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.

  2020cited by this paper
• A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia.

  2020cited by this paper
• ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

  2020cited by this paper
• Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment.

  2020cited by this paper
• Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2020cited by this paper
• Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia

  2020cited by this paper
• Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.

  2020cited by this paper
• Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum.

  2020cited by this paper
• KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

  2020cited by this paper
• A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL.

  2020cited by this paper
• Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study

  2020cited by this paper
• Chromosomes in breast lymphoma.

  2020cited by this paper
• Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

  2020cited by this paper
• Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

  2020cited by this paper
• A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.

  2020cited by this paper
• Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2020cited by this paper
• Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma

  2020cited by this paper
• Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA.

  2020cited by this paper
• Epstein-Barr Virus-Associated Post-transplant Lymphoproliferative Disease.

  2020cited by this paper
• Ibrutinib, Obinutuzumab And Venetoclax In Relapsed and Untreated Patients with Mantle-Cell Lymphoma, a phase I/II trial.

  2020cited by this paper
• Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma.

  2020cited by this paper
• Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment.

  2020cited by this paper
• A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas

  2020cited by this paper
• Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.

  2020cited by this paper
• Del17p without TP53 mutation confers poor prognosis in intensively treated newly diagnosed multiple myeloma patients.

  2020cited by this paper
• Risk factors in MM: is it time for a revision?

  2020cited by this paper
• Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

  2020cited by this paper
• Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.

  2020cited by this paper
• Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations

  2020cited by this paper
• Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy

  2020cited by this paper
• COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

  2020cited by this paper
• Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).

  2019cited by this paper
• Disease‐biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations

  2019cited by this paper
• Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

  2019cited by this paper
• Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

  2019cited by this paper
• Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia

  2019cited by this paper
• Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.

  2019cited by this paper
• Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

  2019cited by this paper
• AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

  2019influential reference
• Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial

  2019cited by this paper
• PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma - Authors' reply.

  2019cited by this paper
• Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

  2019cited by this paper
• Optimizing treatment for HIV-associated lymphoma.

  2019cited by this paper
• Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses

  2019cited by this paper
• Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.

  2019cited by this paper

• Uncovering regulatory B‐cell features associated with regulatory T‐cell expansion and global T‐cell exhaustion in Waldenström macroglobulinemia Myd88 L252P ‐like lymphoplasmacytic lymphomas

  2025cites this paper
• Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel.

  2024cites this paper
• Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel.

  2024cites this paper
• The Updated European Hematology Association Research Roadmap

  2022cites this paper
• Management of ALL in adults: 2024 ELN recommendations from a European expert panel

  year unknowncites this paper